ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
-7.92%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$127M
AUM Growth
+$127M
(-51%)
Cap. Flow
-$96.3M
Cap. Flow
% of AUM
-75.74%
Top 10 Holdings %
Top 10 Hldgs %
72.27%
Holding
39
New
11
Increased
5
Reduced
12
Closed
8
Top Buys
| 1 |
BLU
BELLUS Health Inc.
BLU
|
$5.02M |
| 2 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$3.61M |
| 3 |
Karyopharm Therapeutics
KPTI
|
$2.29M |
| 4 |
CRISPR Therapeutics
CRSP
|
$2.25M |
| 5 |
Axsome Therapeutics
AXSM
|
$1.72M |
Top Sells
| 1 |
Iovance Biotherapeutics
IOVA
|
$30.9M |
| 2 |
Adverum Biotechnologies
ADVM
|
$14.1M |
| 3 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$11.2M |
| 4 |
ATNX
Athenex, Inc. Common Stock
ATNX
|
$9.36M |
| 5 |
Veracyte
VCYT
|
$8.86M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KDMN
1
DELISTED
Kadmon Holdings, Inc.
KDMN
| $16.2M | 11.66% | 6,412,500 -1,205,000 | -16% | -$3.04M |
|
|
2
Iovance Biotherapeutics
IOVA
$807M
| $13.2M | 9.56% | 727,500 -1,699,201 | -70% | -$30.9M |
|
3
Arvinas
ARVN
$568M
| $12.2M | 8.81% | 566,500 +15,500 | +3% | +$334K |
|
4
Arrowhead Research
ARWR
$3.05B
| $10.9M | 7.88% | 387,500 -91,000 | -19% | -$2.56M |
|
|
5
Axsome Therapeutics
AXSM
$6.05B
| $10.6M | 7.63% | 522,500 +85,000 | +19% | +$1.72M |
|
6
Milestone Pharmaceuticals
MIST
$156M
| $6.89M | 4.97% | 369,500 +22,500 | +6% | +$420K |
|
7
Xenon Pharmaceuticals
XENE
$2.98B
| $6.33M | 4.57% | 702,500 +1,000 | +0.1% | +$9.01K |
|
|
8
CRISPR Therapeutics
CRSP
$4.71B
| $5.49M | 3.96% | 134,000 +55,000 | +70% | +$2.25M |
|
9
Protagonist Therapeutics
PTGX
$3.67B
| $5.03M | 3.63% | 418,500 -253,000 | -38% | -$3.04M |
|
|
BLU
10
DELISTED
BELLUS Health Inc.
BLU
| $5.02M | 3.62% | +785,000 | New | +$5.02M |
|
11
Aurinia Pharmaceuticals
AUPH
$1.58B
| $4.54M | 3.28% | 850,000 -85,000 | -9% | -$454K |
|
12
Insmed
INSM
$28.8B
| $3.88M | 2.8% | 220,000 -215,500 | -49% | -$3.8M |
|
|
RETA
13
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $3.61M | 2.61% | +45,000 | New | +$3.61M |
|
|
14
Veracyte
VCYT
$2.39B
| $2.7M | 1.95% | 112,500 -369,000 | -77% | -$8.86M |
|
15
argenx
ARGX
$43.6B
| $2.56M | 1.85% | 22,500 -58,500 | -72% | -$6.67M |
|
|
16
Karyopharm Therapeutics
KPTI
$61.7M
| $2.29M | 1.65% | +237,500 | New | +$2.29M |
|
17
IRIDEX
IRIX
$22.8M
| $2.17M | 1.56% | 1,171,300 | – | – |
|
|
AMRN
18
Amarin Corp
AMRN
$311M
| $1.52M | 1.09% | +100,000 | New | +$1.52M |
|
19
Kura Oncology
KURA
$686M
| $1.44M | 1.04% | +95,000 | New | +$1.44M |
|
|
MRTX
20
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $1.32M | 0.96% | 17,000 -45,500 | -73% | -$3.54M |
|
21
Zymeworks
ZYME
$1.12B
| $1.3M | 0.94% | +52,500 | New | +$1.3M |
|
|
RARX
22
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $1.3M | 0.94% | +55,000 | New | +$1.3M |
|
23
Assembly Biosciences
ASMB
$190M
| $1.29M | 0.93% | 131,500 -26,500 | -17% | -$261K |
|
24
Merus
MRUS
$4.98B
| $1.23M | 0.89% | +69,274 | New | +$1.23M |
|
25
PTC Therapeutics
PTCT
$3.92B
| $1.22M | 0.88% | +36,000 | New | +$1.22M |
|